Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b conjugate vaccine(Sanofi Pasteur SA)(Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b conjugate vaccine(Sanofi Pasteur SA))

概要

基本信息

药物类型

联合疫苗、预防性疫苗、结合疫苗

别名

6-in-1 paediatric vaccine - Sanofi、6-in-1 paediatric vaccine - sanofi pasteur、DTaP-IPV-HB-PRP-T

+ [13]

靶点-

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Sanofi Pasteur Europe

Sanofi Pasteur

非在研机构

Sanofi

最高研发阶段批准上市

首次获批日期

欧盟 (2013-04-17),

白喉嗜血杆菌感染乙型肝炎+ [3]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

28

项与 Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b conjugate vaccine(Sanofi Pasteur SA) 相关的临床试验

NCT06647407 / Recruiting临床1/2期

A Parallel-group Prevention, Phase II, Partially Blinded, Multi-stage Study to Investigate the Immunogenicity and Safety of Pentavalent Meningococcal ABCYW Vaccine Formulations Compared With Licensed Meningococcal Vaccines When Administered Alone in Healthy Children (2 to 9 Years of Age) or Concomitantly With Routine Pediatric Vaccines in Toddlers (12 to 15 Months of Age) and Infants (2 Months of Age).

This study is the first study of Sanofi's Pentavalent Meningococcal ABCYW vaccine clinical development program to be conducted in the pediatric population below 10 years of age. The aim of the study is to assess 2 formulations of the MenPenta vaccine compared to licensed meningococcal vaccines when administered alone in children (Stage 1) or concomitantly with routine pediatric vaccines in toddlers (Stage 2) and infants (Stage 3).
Study details include:
The study duration per participant will be up to 12 months for children in Stage 1 and toddlers in Stage 2 and 16 to-19 months for infants in Stage 3.

开始日期2024-11-05

申办/合作机构

Sanofi Pasteur

NCT05794230 / Active, not recruiting临床3期

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

This open label randomized study will be conducted to evaluate and/or describe the immunogenicity and describe the safety of MenACYW conjugate vaccine when administered in infants and toddlers.
It will be conducted in India and the RSA in 2 cohorts:
* Cohort I: Infants and toddlers 6 months to 16 months of age
* Cohort II: Infants and toddlers 6 weeks to 15 months of age
In Cohort I, eligible participants will be randomized in a 1:1 ratio to receive 2 intramuscular (IM) injections (1+1 vaccination schedule) of either MenACYW conjugate vaccine (Groups 1 and 3) or Menactra vaccine (Groups 2 and 4), co-administered with routine pediatric vaccines.
In Cohort II, eligible participants will be randomized in a 2:1 ratio to receive either 3 IM injections (2+1 vaccination schedule) of MenACYW conjugate vaccine co-administered with routine pediatric vaccines (Groups 5 and 7) or routine pediatric vaccines only (Groups 6 and 8).
The primary objectives of this study are:
* To demonstrate the non-inferiority of immunogenicity of 2 doses of MenACYW conjugate vaccine compared to 2 doses of Menactra® vaccine in infants and toddlers 6 months to 16 months of age in terms of serum bactericidal assay using human complement (hSBA) seroprotection (titers ≥ 1:8) in India and the Republic of South Africa (RSA)
* To demonstrate the vaccine immune sufficiency of 3 doses of MenACYW conjugate vaccine in infants and toddlers 6 weeks to 15 months of age in terms of hSBA seroprotection (titers ≥ 1:8) in India and the RSA
The secondary objectives of this study are:
* To describe the antibody titers to the meningococcal serogroups A, C, Y, and W:
* before and 30 days post primary series of MenACYW conjugate vaccine and before and 30 days post booster dose of MenACYW conjugate vaccine in infants and toddlers 6 weeks to 15 months of age in India and the RSA when administered concomitantly with other age-recommended vaccines.
* before and after 30 days post each dose of MenACYW conjugate vaccine or Menactra vaccine in infants and toddlers 6 months to 16 months of age in India and the RSA when administered concomitantly with other age-recommended vaccines.
* To describe the antibody responses against the antigens of the other age-recommended vaccines when administered concomitantly with MenACYW conjugate vaccine:
* in infants and toddlers 6 weeks to 15 months of age in India and the RSA.
* in infants and toddlers 6 months to 16 months of age in India and the RSA. The duration of each participant's active participation in the study will be approximately 10 to 11 months for Cohort I and 13,5 to 14,5 months for Cohort II.

开始日期2023-03-27

申办/合作机构

Sanofi Pasteur

ChiCTR2200064991 / Suspended临床3期

A randomized, blinded, parallel-controlled phase III clinical study to evaluate the safety and immunogenicity of healthy infants aged 2 and 3 months with DTacp

开始日期2022-10-26

申办/合作机构

河南省疾病预防控制中心

100 项与 Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b conjugate vaccine(Sanofi Pasteur SA) 相关的临床结果

登录后查看更多信息

100 项与 Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b conjugate vaccine(Sanofi Pasteur SA) 相关的转化医学

登录后查看更多信息

100 项与 Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b conjugate vaccine(Sanofi Pasteur SA) 相关的专利（医药）

登录后查看更多信息

107

项与 Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b conjugate vaccine(Sanofi Pasteur SA) 相关的文献（医药）

2024-12-31·Human Vaccines & Immunotherapeutics

Rejoinder to comments on ‘‘Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China’’

Article

作者: Amimo, Floriano

2024-12-31·Human Vaccines & Immunotherapeutics

A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

Article

作者: Lumley, Jessie ; Chen, Ziqiang ; Costantino, Claudio ; Johnson, David ; Westerholt, Soeren ; Martinon-Torres, Federico ; Lambeth, Courtney ; Guerra, Andrea ; Marcek, Tomas ; Wilck, Marissa

DTaP5-HBV-IPV-Hib (Vaxelis®) is a hexavalent combination vaccine (HV) indicated in infants and toddlers for the prevention of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. Switching between HVs during the childhood vaccination series is sometimes necessary due to, for example, vaccine availability, health-care provider preference, and/or tender awards. The purpose of this study was to describe the safety, tolerability, and immunogenicity of a booster dose of Vaxelis® in participants who previously received a primary infant series of either DTaP2-HBV-IPV-Hib (Hexyon®) or Vaxelis®. Healthy participants approximately 11-13 months of age who previously received a two-dose primary series of Hexyon® (HHV group) or Vaxelis® (VVV group) all received a Vaxelis® booster dose. Immunogenicity was evaluated by measuring antibody levels to individual vaccine antigens approximately 30 days following booster vaccination. Safety was evaluated as the proportion of participants with adverse events (AEs). The proportions of participants with antibody-specific responses for antigens contained in both Vaxelis® and Hexyon® at 30 days post-toddler-booster vaccination with Vaxelis® were comparable between groups, and higher in the VVV group for Vaxelis® antigens PRN and FIM2/3. The overall proportions of participants with AEs were generally comparable between groups. Following a booster dose of Vaxelis®, immune responses were comparable between groups for all shared antigens, and higher in the VVV group for antigens found only in Vaxelis®. The booster was well tolerated in both groups. These data support the use of Vaxelis® as a booster in mixed HV regimens.

2024-12-31·Human Vaccines & Immunotherapeutics

Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China

Article

作者: Zhang, Bingling ; Tang, Lin ; Liu, Jiajie ; Huang, Lifang ; Wang, Yu ; Wang, Lei ; Xu, Xia ; Wang, Fuzhen ; Li, Jun ; Zhang, Xue ; Zhou, Yang ; Liu, Qianqian ; Huang, Aodi ; Zhang, Qian ; Liu, Siyu ; Zhou, Zemei ; Yin, Zundong ; Wang, Xiaoqi

DTaP-HBV-IPV-Hib hexavalent vaccine has been used in high-income countries for many years to prevent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive Haemophilus influenzae type b disease. Currently, no hexavalent vaccines have been approved for use in China. Evidence of parental acceptance and interest in hexavalent vaccines can help policy makers and manufacturers make decisions about entering the vaccine market and the immunization program in China. We measured parental acceptance and willingness-to-pay (WTP) for a hexavalent vaccine to provide such evidence. We conducted a cross-sectional survey of children's caregivers in 16 vaccination clinics in seven cities in China and obtained information on socio-demographics, knowledge of disease, confidence in vaccines, previous vaccination experience, and acceptance of and WTP for hexavalent vaccine. Multivariate logistic regression was used to determine factors influencing acceptance, and multivariate tobit regression was used to identify factors impacting WTP. Between April 28 and June 30, 2023, a total of 581 parents of children aged 0-6 years participated in the survey; 435 (74.87%, 95% CI:71.3%-78.4%) parents indicated acceptance of hexavalent vaccine. Residence location, parents' education level, experience paying for vaccination, and disease knowledge scores were key factors affecting parents' choices for vaccination. Mean (SD) and median (IQR) willingness to pay for full 4-dose course vaccination were 2266.66 (1177.1) CNY and 2400 (1600-2800) CNY. Children's age (p < .001), parents' education level (p = .024), and perceived price barriers (p < .001) were significantly associated with WTP. Parents have high acceptance and willingness to pay for hexavalent vaccine. The less money parents have to pay out of pocket, the more willing they can be to accept the vaccine. Therefore, acceptance may increase even further if the vaccine is covered by medical insurance, provided free of charge by the government, or if its price is reduced. Our results provide reference for optimizing and adjusting immunization strategies in China.

2

项与 Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b conjugate vaccine(Sanofi Pasteur SA) 相关的新闻（医药）

2023-09-25

·Pharmaceutical Technology

Valneva receives JE vaccine supply contract from US DoD

Valneva will supply a minimum of $32m worth of IXIARO vaccines to the US DoD. Credit: MasterTux from Pixabay. Valneva has received a contract from the US Department of Defense (DoD) for the delivery of its Japanese encephalitis (JE) vaccine, IXIARO. The company will supply a minimum of $32m worth of IXIARO vaccines as part of the new one-year contract. Recommended Reports Reports LOA and PTSR Model - Dtcp Vaccine in Tetanus GlobalData Reports LOA and PTSR Model - DTwP-Hep B-IPV-Hib Vaccine in Poliomyelitis GlobalData View all Companies Intelligence Valneva SE Dod View all DoD can also purchase additional doses during the next 12 months. Deliveries of the vaccines will begin immediately. IXIARO is the only JE vaccine that has received approval from the US Food and Drug Administration (FDA). Valneva developed the vaccine through a research and development agreement with the Walter Reed Army Institute of Research. The company is responsible for marketing and supplying this vaccine directly to the military and private travel market in the US. Valneva chief commercial officer Dipal Patel stated: “We are excited to continue our long-term relationship with the DoD. “The US military has trusted IXIARO for over ten years to help protect military personnel, their families, civilian government service personnel and government contractors from this potentially deadly disease.” JE is an infectious disease endemic in South-East Asia, China and India. It has a fatality rate of around 30% in symptomatic patients and causes permanent brain damage in half of those who survive. JE killed more than 1,200 children in one month during an epidemic outbreak in the Indian state of Uttar Pradesh and Nepal.

疫苗上市批准

2021-03-01

·药融圈

从法国走向世界，跨国医药龙头赛诺菲的布局

▲速抢免费参会名额 | 大湾区(广州)生物医药创新者峰会注：本文不构成任何投资意见和建议，以上市公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐。 “致力于帮助人们应对健康挑战，致力于将科学创新转化为医疗健康解决方案，让生命绽放。”——赛诺菲今日的赛诺菲（Sanofi），经历了赛诺菲、圣德拉堡、赫斯特、罗纳普朗克乐安等公司的一系列合并。这些公司已积累了超过一个世纪的医药经验，而创新是其满足社会发展和患者需求的核心。近20来年的巨大合并/并购：1999年Sanofi与Synthélabo合并成立Sanofi-Synthélabo。2004年，Sanofi-Synthélabo与安万特（Aventis）合并，并更名为赛诺菲-安万特（ Sanofi-Aventis）。2011年5月，公司更名为赛诺菲。目前，在全球140多个国家有全职雇员超过100000人；是一家全球领先的医药健康企业，赛诺菲主要在处方药市场从事药物的研发、生产和销售，同时也开发非处方药；此前还有欧洲前几的API业务。公司涵盖七个主要治疗领域：心血管、中枢神经系统、糖尿病、内科、肿瘤、血栓和疫苗。主要领域 1、处方药：赛诺菲在心血管疾病、糖尿病、肿瘤、中枢神经系统疾病、内科疾病等领域拥有创新药产品。 2、疫苗：赛诺菲旗下疫苗事业部赛诺菲巴斯德是世界领先的疫苗生产企业。在预防流感、肺炎和儿童疾病等领域拥有创新的疫苗产品。 3、消费者保健业务 2020全年公司主要经营状况 2020年，赛诺菲推行“全力致胜”战略取得了显著成绩，加强了研发管线，特别是在肿瘤、炎症和免疫系统疾病上，将节流资金用于投资推动增长研发管线，全年销售额达到360.41亿欧元，恒定汇率下增长率为3.3%。企业每股收益5.86欧元，增长3.9%，恒定汇率增长9.2%，高于预期的7% ～ 8%。不仅如此，2020年全年赛诺菲实现成本节约16.8亿欧元，其中约60%用于再投资。 2020全年公司各业务具体表现 ▲2020财年产品业绩1 其中，特药业务收入为109.54亿欧元，主要受达必妥（Dupixent®）强劲增长的影响，该在皮肤科具有领先作用的生物产品在2020年销售额连续提高，恒定汇率下增长了74%。肿瘤治疗领域新产品上市也推动了业绩，同时也有阿仑单抗（Lemtrada®）每季度销售额达到2000万至2500万欧元的影响。然而由于市场竞争激烈的缘故，多发硬化症领域特立氟胺（Aubagio®）销售额增长放缓。 ▲2020财年产品业绩2 普药收入为147.2亿欧元，恒定汇率下总体下降7.6%，主要是因为由于受COVID - 19大流行影响，在美国地区的特许经营销售额在恒定汇率下下降了20%，之前在中国市场广受欢迎的硫酸氢氯吡格雷片（Plavix）和厄贝沙坦氢氯噻嗪片（Aprovel）的销量在恒定汇率下也分别下降了30.1%和15.9%，然而依诺肝素（Lovenox®）全球销售额却因为新冠病毒流行在恒定汇率下增长了5%，甘精胰岛素（Toujeo®）同比增长了8.4%。 ▲2020财年产品业绩3 疫苗业务收入为59.73亿欧元，主要是由于流感疫苗销售额创下记录，突破20亿欧元大关，在恒定汇率下增长38%。其他方面，因为液态六合一儿童疫苗（Hexaxim®）在销售地区的扩张和正处于有利的脊髓灰质炎销售阶段，PPH类销售额在恒定汇率下增长13%。消费者保健业务收入为43.94亿欧元，恒定汇率下总体下降1.9%。主要是受新冠病毒的影响，消化系统方面和咳嗽感冒特许经营销售额恒定汇率下销售额分别下降了8.6%和5.3%，主要是受欧洲地区疫情较为严重导致销售额大幅降低的影响。 2020上半年公司主要经营状况 2020上半年，赛诺菲净销售额171.8亿欧元，较2019年同比增长0.9%；毛利润达122.11亿欧元，受疫情影响，低于2019年上半年的123.08亿欧元，同比下降0.8%，但是最后的营业收入比19年同期增长数倍，主要得益于公司上半年核心业务驱动，在研发转型方面取得重大成果，例如达必妥（Dupixent®，与Regeneron合作开发）的销售额大量增长。其净销售额为16.3亿欧元(恒定汇率下增长+93.8% )，是赛诺菲的王牌产品。2020年6月，达必妥在中国获批用于治疗成人中重度特应性皮炎，包括中国在内，它目前已在44个国家上市治疗该病，同时在18个国家用于哮喘治疗。赛诺菲在本次上半年年报中重申了他们的目标，对达必妥的销售峰值预期超过100亿欧元。 2020上半年按地区划分的净销售额 2020年上半年，赛诺菲在美国的净销售额达到58.8亿欧元，同比增长8.9%。这是由于Dupixent®( 13.1亿欧元)和Aubagio®( 7.75亿欧元)的坚实业绩，完全抵消了Lantus(- 4.74亿欧元)和Zantac(- 6800万欧元)销售额的下降以及因对疫苗接种的负面影响导致的疫苗部分销售额的下降(- 4.91亿欧元)的影响。在欧洲，2020年上半年净销售额同比下降2.4%，为43.45亿欧元。这主要是因为Lovenox®，Lemtrada®和Lantus®的销售额下降。在世界其他地区，上半年净销售额下降3.0%至69.55亿欧元。Dupixent®和特殊护理GBU以及糖尿病业务的良好销售业绩被Plavix®和Aprovel®、疫苗(受Covid-19影响)和CHC消化类产品的销售额下降所抵消。在中国，尽管Plavix®和Aprovel®家族的销售额显著增长，但受VBP（国家药品集中采购）导致的净销售额下降的影响，中国地区销售额同比下降了13.3%至13.07亿欧元，今年上半年，非VBP产品在中国的销量增长了20.7%。在日本，尽管Dupixent®表现强劲，但由于心血管及处方药特许经营和疫苗的销售额下降，上半年净销售额下降7.1%至9.26亿欧元。 2020上半年，赛诺菲全球核心业务具体表现 ▲2020上半年产品业绩在2020年上半年，赛诺菲的全球销售额达到130.2亿欧元（158.1亿美元），同比增长2.4%。其中多发性硬化症、神经系统疾病、其他炎症疾病和免疫类(+ 8400万欧元)、罕见疾病类(+ 7600万欧元)、肿瘤(+ 7000万欧元)和罕见血液疾病(+ 2800万欧元)等药物销售成绩优异，各业务版块具体销售表现如下： 1、多发性硬化症、神经系统疾病、其他炎症疾病和免疫药物的净销售额为12.53亿欧元，同比增长8.9%。 2、罕见病药物的净销售额为15.32亿欧元，同比增长4.1%。 3、心血管和处方药的净销售额为51.42亿欧元，同比下降11.6%，关键原因包括Lovenox®在欧洲的销售额下降，以及由于2019年12月推出VBP计划后的价格调整，Aprovel®系列产品在中国的净销售额下降。在2020年上半年，Plavix®的净销售额为5.09亿欧元，同比跌幅达33%，主要是由于在中国的销售额下降(2.05亿欧元)，这与VBP计划（为进一步降低药费负担，规范药品流通秩序，探索完善药品集中采购机制和以市场为主导的药价形成机制）的价格调整有关，且由于2019年10月起实施降价，Plavix®在日本的净销售额也下降至5800万欧元。 4、2020年上半年，由于Lantus®在美国和欧洲的销售额下降，赛诺菲全球糖尿病销售额为24.76亿欧元，同比下降4.2%。 5、肿瘤业务净销售额增长24.2%，达3.75亿欧元，所有地区均实现两位数增长。 6、疫苗业务净销售额为18.36亿欧元，同比下降3.1%。其中，流感疫苗在美国市场增长200%是由于北半球的流感季节较晚，受COVID - 19相关刺激导致南半球的出货量增加。今年上半年流感疫苗的销售大幅增长(1.79亿欧元)，间接抵消了新冠病毒对美国疫苗接种的负面影响导致PPH疫苗在美国销售额的降低（1.83亿欧元），而在欧洲PPH疫苗销售额则是增长到了1.62亿欧元。旅行和其他地方性疫苗上半年全球均有超过40%的跌幅，净销售额下降到了1.54亿欧元，这与受COVID - 19大流行相关的旅行限制的影响较大。研发管线 ▲根据药融云数据库显示，截至到2021年2月17日，搜索赛诺菲全球药物研发共有1597条药物信息，详细产品信息可登录药融云数据库查看截至2020年12月31日，赛诺菲现有研发管线拥有44个后期临床开发中的新分子实体(或已提交监管机构审评审批)。在研项目中，抗肿瘤药物仍然占了很大一部分。即便社会在进步，癌症仍然是全球第二大死亡原因。赛诺菲正将其在小分子研究方面的广泛传统与新的生物技术相结合，推动癌症治疗向前发展。为了实现这一目标，公司利用了多种技术平台，包括单克隆抗体、信使RNA (mRNA)和抗体偶联药物物（ADC）——抗体被用作一种独特的递送系统，将药物递送到需要的地方，以对抗体内的癌症。 SAR408701是赛诺菲的首个潜在靶向CEACAM5(癌胚抗原相关细胞粘附分子5)的类抗体偶联药物，CEACAM5是一种细胞表面糖蛋白，在非鳞状非小细胞肺癌(NSCLC)中高度表达。大约20-30%的肺癌有高表达CEACAM5，临床前疗效数据支持其在肺癌和胃肠道肿瘤中的有效治疗。赛诺菲致力于研究治疗多发性骨髓瘤的新疗法。多发性骨髓瘤是一种难以治疗的血癌，通常需要多种疗法。Sarclisa是一种单克隆抗体，可与多发性骨髓瘤细胞上的CD38受体结合。目前，它在美国和欧盟被批准与pomalidomide和地塞米松联合使用，用于之前接受过至少两种疗法(包括来那度胺和一种蛋白酶体抑制剂)的某些成人的治疗。预计未来研发项目后续主要研发时间线赛诺菲表示，其三分之二的资产具有开发成一流药物的潜力，成本的控制有助于盈亏平衡，使得他们的研发效率大大增加。公司目前最畅销的药物之一是可注射的生物制剂Dupixent；具体参见，重磅良药：特应性皮炎Dupixent国内售价出炉；百亿重磅度普利尤单抗进医保，IL-4R抗体在研激烈。 ▲2019/2020财年全球Dupixent®季度销售额(以百万欧元为单位)） Venglustat是一种建立在Sanofi Genzyme罕见病遗传基础上的药物，未来要为它开发几种单基因疾病的治疗，包括戈谢病3型、法布里病和GM-2神经节抑制剂等罕见疾病，还有就是常染色体显性多囊肾病和帕金森病。研发团队致力于投资多靶向治疗，用一种药物治疗多种疾病，进行联合治疗，使得治疗效果更显著，开发新的生物制剂以生产精准药物，开展突破性研究，释放基因在治疗方面的潜力，未来利用人工智能和创新数字技术使患者能够更好地管理慢性疾病。发展历程 1973年，以Labaz,Castaigne和Robilliart等制药企业和一些化妆品制造公司为基础组建了一个名为“Sanofi”（赛诺菲）的子公司 1979年，在巴黎股票交易所独立上市 1980年，与CM Industries的医药部门Clin-Midy进行合并，公司的规模扩大了50% 1983年，收购了Ronchèse，获得动物保健业务 1994年，推出思而赞®（注射用伊米苷酶）来治疗一型戈谢病患者 1996年，从铂衍生而来的乐沙定®（奥沙利铂）问世，该药品于2004年因创新性抗癌疗法获得法国盖伦奖 1998年，与Synthlabo合并 2000年，赛诺菲推出来得时®，这是一种长效重组人胰岛素 2004年，收购当时法国最大的制药集团巴黎的安万特集团，组成了赛诺菲.安万特公司 2006年，推出美而赞®（α-阿糖苷酶）用于治疗庞贝病 2011年，收购了BMP太阳石，强化了在中国的感冒咳嗽及女性健康的消费者保健平台，以助力在中国的业务发展，同年收购了Genzyme，公司名去掉了后缀，称作“Sanofi” 2013年，在美国市场推出新型四价流感疫苗，至2015年推广到20多个国家 2015年，推出Cerdelga®（依鲁司他），这是一种治疗一型戈谢病的口服药物，联合再生元制药公司研发并推出治疗高胆固醇血症患者的Praluent® 2017年，收购Protein Sciences，获得疫苗新技术 2018年，收购了Ablynx和Bioverativ，巩固了其在罕见病领域的领先地位 2019年，小儿麻痹症灭活疫苗全世界推广结语赛诺菲首席执行官Paul Hudson评论道：“虽然去年对所有人来说都是极具挑战性的一年，但我依然对赛诺菲在全球大流行病背景下取得可观的进展感到非常自豪。我们在世界各地的团队坚持不懈地贯彻赛诺菲的战略，专注于提高运营和财务效率，完成了对Synthorx和Principia的收购，拓宽了研发管线，将我们的重要药物带给了更多患者。我们将继续开发两种COVID-19候选疫苗。未来，希望能够通过努力去拯救更多的生命。”赛诺菲从前身成立至今的100多年内，经过不断并购、吸收各类公司，并将其经验纳为己用，逐渐成长为如今的制药航母，他们的成功与公司本身正确决策分不开，赛诺菲研发优势巨大，管线丰富，往后的市场竞争优势会越来越大。参考： NMPA/CDE；药融云数据，www.pharnexcloud.com； FDA/EMA/PMDA；相关公司公开披露；赛诺菲官网； https://www.sanofi.cn/zh/about-us/sanofi-group； MeetEUROAPI: Sanofi christens to-be-spun-off drug ingredients business,taps CEO | FiercePharma； http://www.pharmatimes.com/news/sanofi_touts_pipeline_with_18_new_drugs_by_2020_1002798 https://pharmaintelligence.informa.com/resources/product-content/exploring-sanofis-revamped-io-pipeline； https://www.biospace.com/article/sanofi-streamlines-pipeline-focus-while-looking-ahead-to-treating-patients-in-a-post-covid-19-world/；等等。【关于药融圈】药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。点分享点点赞点在看

疫苗并购抗体财报抗体药物偶联物

100 项与 Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b conjugate vaccine(Sanofi Pasteur SA) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07CA09	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
白喉	冰岛	Sanofi Pasteur	2013-04-17
白喉	列支敦士登	Sanofi Pasteur Europe	2013-04-17
白喉	冰岛	Sanofi Pasteur Europe	2013-04-17
白喉	挪威	Sanofi Pasteur Europe	2013-04-17
脊髓灰质炎	列支敦士登	Sanofi Pasteur Europe	2013-04-17
脊髓灰质炎	冰岛	Sanofi Pasteur	2013-04-17
脊髓灰质炎	挪威	Sanofi Pasteur Europe	2013-04-17
脊髓灰质炎	欧盟	Sanofi Pasteur	2013-04-17
脊髓灰质炎	冰岛	Sanofi Pasteur Europe	2013-04-17
脊髓灰质炎	欧盟	Sanofi Pasteur Europe	2013-04-17
脊髓灰质炎	列支敦士登	Sanofi Pasteur	2013-04-17
脊髓灰质炎	挪威	Sanofi Pasteur	2013-04-17
破伤风	欧盟	Sanofi Pasteur Europe	2013-04-17
破伤风	欧盟	Sanofi Pasteur	2013-04-17
破伤风	列支敦士登	Sanofi Pasteur Europe	2013-04-17
破伤风	列支敦士登	Sanofi Pasteur	2013-04-17
破伤风	冰岛	Sanofi Pasteur Europe	2013-04-17
破伤风	挪威	Sanofi Pasteur	2013-04-17
破伤风	挪威	Sanofi Pasteur Europe	2013-04-17
破伤风	冰岛	Sanofi Pasteur	2013-04-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	临床3期	南非	Sanofi Pasteur	2016-07-14
嗜血杆菌感染	临床1期	秘鲁	Sanofi Pasteur	2006-07-01
嗜血杆菌感染	临床1期	墨西哥	Sanofi Pasteur	2006-07-01
流感病毒感染	临床1期	菲律宾	Sanofi Pasteur	2006-06-01
白喉	临床1期	阿根廷	Sanofi	2006-02-01
乙型肝炎	临床1期	阿根廷	Sanofi	2006-02-01
脊髓灰质炎	临床1期	阿根廷	Sanofi	2006-02-01
破伤风	临床1期	阿根廷	Sanofi	2006-02-01
百日咳	临床1期	阿根廷	Sanofi	2006-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03673462 (MET41, CTgov)	临床3期	脑膜炎球菌感染	2,797	W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus+Varicella Virus Vaccine+Hepatitis B Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Group 1: MenACYW Conjugate Vaccine)	鬱選鏇衊築簾鹹構糧襯(壓獵憲顧蓋廠糧廠廠窪) = 艱蓋繭範淵襯鬱蓋糧鹹獵願遞鹹遞鬱餘鏇糧艱 (鏇觸餘餘遞壓繭繭鑰繭, 壓淵蓋鏇窪衊淵觸襯糧 ~ 鬱選獵襯繭廠廠積齋壓) 更多	-	2023-10-05
				W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus+Varicella Virus Vaccine+Hepatitis B Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Group 2: MENVEO®)	鬱選鏇衊築簾鹹構糧襯(壓獵憲顧蓋廠糧廠廠窪) = 窪餘鬱鏇簾齋範網憲憲獵願遞鹹遞鬱餘鏇糧艱 (鏇觸餘餘遞壓繭繭鑰繭, 夢範鬱築築淵製餘鏇鹽 ~ 糧艱夢鬱鏇獵顧築齋壓) 更多
NCT01444781 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 百日咳 \| 破伤风 \| 脊髓灰质炎	1,106	DTaP IPV Hep B PRP T+Prevenar (Group 1: DTaP IPV Hep B PRP T + Prevenar™ Primary and Booster)	網製選簾醖衊醖構憲衊(齋餘夢網鹹繭製願遞繭) = 蓋壓窪齋鏇憲醖觸淵獵衊鬱襯鹽壓憲膚築鬱壓 (糧憲鹽夢鑰餘製糧糧憲, 廠願醖廠獵網糧夢壓膚 ~ 觸製鑰築鹽壓範鹹鹹繭) 更多	-	2014-07-16
				IPV Hep B PRP T Primary+Infanrix Hexa+PCV7 (Group 2DTaP IPV Hep B PRP T Primary/Infanrix Hexa+PCV7 Booster)	網製選簾醖衊醖構憲衊(齋餘夢網鹹繭製願遞繭) = 膚選襯蓋築繭鑰壓繭淵衊鬱襯鹽壓憲膚築鬱壓 (糧憲鹽夢鑰餘製糧糧憲, 鏇艱獵繭顧觸鬱製選鹹 ~ 廠築襯鑰糧觸憲顧選襯) 更多
NCT00404651 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 百日咳 \| 破伤风 \| 脊髓灰质炎	1,189	DTaP-IPV-HB-PRP~T (DTaP-IPV-HB-PRP~T Batch 1)	蓋膚獵憲鏇構膚遞觸顧(鑰遞鏇窪選顧餘製蓋窪) = 膚築觸衊淵網遞淵襯齋壓襯齋顧簾遞醖鹹鏇遞 (餘齋範餘範襯鬱齋鏇築, 繭艱鹽製淵顧壓積繭願 ~ 醖顧蓋醖齋淵願膚獵遞) 更多	-	2014-05-09
				DTaP-IPV-HB-PRP~T (DTaP-IPV-HB-PRP~T Batch 2)	蓋膚獵憲鏇構膚遞觸顧(鑰遞鏇窪選顧餘製蓋窪) = 製醖積蓋網鹽網鏇膚鑰壓襯齋顧簾遞醖鹹鏇遞 (餘齋範餘範襯鬱齋鏇築, 築蓋範製鬱膚鏇蓋糧膚 ~ 製壓鑰積鏇選鏇獵鑰艱) 更多
NCT01177722 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 百日咳 \| 破伤风 \| 脊髓灰质炎	1,375	DTap-IPV-Hep B-PRP~T (DTap-IPV-Hep B-PRP~T Batch A)	範範鏇鹽衊觸壓壓齋衊(鑰窪壓繭鹽築鑰衊鹽齋) = 醖範積窪範夢窪獵窪窪鹽淵糧夢製鏇顧鬱餘齋 (鏇艱蓋廠膚壓繭糧憲鹽, 鑰簾製製淵鑰憲願餘夢 ~ 鏇製範網顧衊夢製淵繭) 更多	-	2014-05-05
				DTaP-IPV-Hep B-PRP~T (DTaP-IPV-Hep B-PRP~T Batch B)	範範鏇鹽衊觸壓壓齋衊(鑰窪壓繭鹽築鑰衊鹽齋) = 選鹽壓簾鹹蓋網醖顧窪鹽淵糧夢製鏇顧鬱餘齋 (鏇艱蓋廠膚壓繭糧憲鹽, 簾蓋簾遞積範遞壓遞齋 ~ 壓艱網鏇衊鏇範齋構觸) 更多
NCT00362336 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 嗜血杆菌感染 \| 百日咳	622	DTaP+DTaP-IPV-Hep B-PRP~T (DTaP-IPV-Hep B-PRP~T Group)	餘鏇鹹遞餘蓋繭夢窪製(鑰鑰鬱憲窪範網齋構鹹) = 壓構廠淵網憲齋構鹽範壓觸範憲壓簾鑰遞構壓 (膚願選糧繭艱鏇鹹膚簾, 鬱鹹製範壓願遞範網顧 ~ 襯繭壓衊選艱膚繭鬱齋) 更多	-	2014-05-02
				CombAct-Hib+Engerix B+OPV (CombAct-Hib™ + Engerix B™ + OPV Group)	餘鏇鹹遞餘蓋繭夢窪製(鑰鑰鬱憲窪範網齋構鹹) = 膚艱遞積衊衊製簾築窪壓觸範憲壓簾鑰遞構壓 (膚願選糧繭艱鏇鹹膚簾, 積憲鹹積遞壓襯壓窪窪 ~ 積網獵積蓋鹽膚網顧衊) 更多
NCT00619502 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 百日咳 \| 脊髓灰质炎	254	DTaP-IPV-HepB-PRP~T (DTaP-IPV-HepB-PRP~T)	憲顧壓積膚淵願獵鹹鏇(顧膚遞構鏇糧鑰襯餘鬱) = 獵壓廠鹽簾簾廠構鬱蓋衊憲艱夢遞餘廠窪構壓 (鏇鑰糧築顧醖淵積鬱簾, 鬱網襯遞願製蓋鏇選憲 ~ 壓範膚蓋憲鏇壓憲築製) 更多	-	2014-04-03
				Engerix B+Pentaxim (Pentaxim™ + Engerix B™)	憲顧壓積膚淵願獵鹹鏇(顧膚遞構鏇糧鑰襯餘鬱) = 壓鑰鬱鹽壓壓夢淵壓製衊憲艱夢遞餘廠窪構壓 (鏇鑰糧築顧醖淵積鬱簾, 糧襯選廠願網夢淵觸齋 ~ 艱餘範蓋襯繭餘鏇觸選) 更多
NCT00315055 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 百日咳	310	DTaP-IPV-Hep B-PRP~T (DTaP-IPV-Hep B-PRP~T)	鑰鹽齋網憲醖築築鏇鬱(觸繭製襯鬱糧窪窪遞繭) = 獵鏇鬱憲淵鏇醖壓窪鑰構淵鹽構網繭積糧餘築 (艱窪選膚鹹鑰選獵網築, 製顧淵範鹽艱網憲鹽鑰 ~ 衊簾範鑰鹽艱襯網顧構) 更多	-	2014-02-04
				ENGERIX+PENTAXIM (PENTAXIM™ and ENGERIX® PEDIATRIC)	鑰鹽齋網憲醖築築鏇鬱(觸繭製襯鬱糧窪窪遞繭) = 窪衊範蓋鏇遞壓鑰鏇觸構淵鹽構網繭積糧餘築 (艱窪選膚鹹鑰選獵網築, 襯襯構簾壓製蓋膚繭製 ~ 構製夢壓築遞醖網範繭)
NCT00831311 (CTgov)	临床2期	白喉 \| 嗜血杆菌感染 \| 百日咳 \| 破伤风 \| 脊髓灰质炎	624	DTaP-IPV-Hep B-PRP~T (Group 1: DTaP-IPV-Hep B-PRP~T)	蓋鏇製願鑰願積蓋蓋齋(鏇淵艱憲網鑰鑰膚淵夢) = 選鏇憲廠襯齋鏇淵艱蓋範膚夢廠襯簾糧壓築繭 (憲襯鬱壓鬱繭壓鑰壓糧, 餘糧繭窪淵繭積糧鬱艱 ~ 鹽齋遞淵鏇膚築遞觸夢) 更多	-	2013-11-21
				ENGERIX B+PENTAXIM (Group 2: PENTAXIM™ and ENGERIX B®)	蓋鏇製願鑰願積蓋蓋齋(鏇淵艱憲網鑰鑰膚淵夢) = 顧夢鹹鑰網鑰艱襯繭窪範膚夢廠襯簾糧壓築繭 (憲襯鬱壓鬱繭壓鑰壓糧, 窪鏇簾鹹範夢衊餘鬱襯 ~ 製壓網鹽襯鑰獵壓壓選) 更多
NCT00514709 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 百日咳 \| 破伤风 \| 流感病毒感染	1,843	DTaP-Hep B-PRP~T+OPV (Group 1: DTaP-Hep B-PRP~T + OPV)	築憲簾鑰艱廠鏇範鏇選(廠壓範憲鏇觸衊夢鑰蓋) = 積鹽簾醖選鏇憲夢選簾繭襯簾憲築糧窪願壓選 (網範繭淵遞壓鬱憲鏇觸, 蓋獵膚蓋鏇構蓋窪範遞 ~ 積範遞醖餘選遞齋醖醖) 更多	-	2013-11-14
				Tritanrix-Hep B+OPV (Group 2: Tritanrix-Hep B/ Hib™ + OPV)	築憲簾鑰艱廠鏇範鏇選(廠壓範憲鏇觸衊夢鑰蓋) = 憲糧糧鹹襯積範夢餘選繭襯簾憲築糧窪願壓選 (網範繭淵遞壓鬱憲鏇觸, 鹽憲衊淵廠餘繭齋簾醖 ~ 窪齋繭繭艱鏇廠蓋繭艱) 更多
NCT00348881 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 百日咳 \| 破伤风 \| 流感病毒感染	2,133	DTaP-Hep B-PRP~T+OPV (Group 1: DTaP-Hep B-PRP~T + OPV)	鬱網憲鑰遞艱製廠構夢(廠鬱淵衊顧蓋蓋醖夢構) = 糧鏇淵蓋齋築顧鑰網網構齋壓齋鬱鑰築鬱簾壓 (築鹽鹹衊鏇蓋蓋獵膚範, 憲鏇壓壓觸糧築選獵餘 ~ 齋鑰範壓窪壓壓糧製簾) 更多	-	2013-10-22
				Tritanrix-Hep B+OPV (Group 2: Tritanrix-Hep B/ Hib™ + OPV)	鬱網憲鑰遞艱製廠構夢(廠鬱淵衊顧蓋蓋醖夢構) = 鹹衊構顧憲顧蓋餘積糧構齋壓齋鬱鑰築鬱簾壓 (築鹽鹹衊鏇蓋蓋獵膚範, 築壓選艱鹽顧積構窪蓋 ~ 襯觸鑰鬱餘餘壓範廠範) 更多